Forced expression of PARK2 rendered breast cancer cells more sensitive to docetaxel and vinorelbine in both MCF-7 and MDA-MB-231 cells (Figure 2A and S2A), but overexpression of PARK2 did not change the sensitivity of DNA-damaging drugs (Figure S2B). This evidence concerns the gene PRKN and breast carcinoma.